

Company Number: 441795

Peter Fox Pharmacy Holdings Limited
Abridged Unaudited Financial Statements
for the financial year ended 30 June 2025

Peter Fox Pharmacy Holdings Limited
CONTENTS

	Page
Statement of Financial Position	3
Notes to the Financial Statements	4 - 6

Peter Fox Pharmacy Holdings Limited
STATEMENT OF FINANCIAL POSITION

as at 30 June 2025

	Notes	2025 €	2024 €
Fixed Assets			
Investments	4	<u>2,884,000</u>	<u>2,884,000</u>
Current Assets			
Cash at bank and in hand		2,170	2,170
Creditors: amounts falling due within one year	5	<u>(2,152)</u>	<u>(2,152)</u>
Net Current Assets		<u>18</u>	<u>18</u>
Total Assets less Current Liabilities		<u><u>2,884,018</u></u>	<u><u>2,884,018</u></u>
Capital and Reserves			
Called up share capital presented as equity		100	100
Share premium account	6	669,708	669,708
Revaluation reserve	6	1,465,000	1,465,000
Retained earnings	6	<u>749,210</u>	<u>749,210</u>
Shareholders' Funds		<u><u>2,884,018</u></u>	<u><u>2,884,018</u></u>

We as Directors of Peter Fox Pharmacy Holdings Limited, state that -

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 359 are satisfied,
- (c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),
- (d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,
- (e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the micro companies' regime.

Approved by the board on 31 October 2025 and signed on its behalf by:

Peter Fox
Director

Patricia Fox
Director

Peter Fox Pharmacy Holdings Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

1. General Information

Peter Fox Pharmacy Holdings Limited is a company limited by shares incorporated in Ireland. C/O Duggan & Power, Emmet Square, Birr, Co. Offaly is the registered office, which is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Directors' Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 30 June 2025 have been prepared on the going concern basis and in accordance with FRS 105 "The Financial Reporting Standard for Micro-Entities applicable in the UK and Republic of Ireland" (FRS 105).

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 105 "The Financial Reporting Standard applicable to the Micro-Entities Regime" issued by the Financial Reporting Council.

The company qualifies as a micro company as defined by section 280D of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Micro Companies Regime' in accordance with section 280E of the Companies Act 2014 and FRS 105.

Accounting Convention

The financial statements are prepared under the historical cost convention.

Consolidated accounts

The company is entitled to the exemption provided for in section 293 (1A) of the Companies Act 2014 from the obligation to prepare group accounts because it qualifies as a micro company in accordance with the micro companies' regime.

Investments

Investments held as fixed assets are stated at cost less provision for any permanent diminution in value. Income from other investments together with any related withholding tax is recognised in the profit and loss account in the year in which it is receivable.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Employees

The average monthly number of employees, including directors, during the financial year was 0.00|0, (2024 - 0).

Peter Fox Pharmacy Holdings Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

4. Investments			Subsidiary undertakings shares	Total
			€	€
Investments Cost				
At 30 June 2025			11,029,555	11,029,555
			<u> </u>	<u> </u>
Provision for diminution in value:				
At 30 June 2025			8,145,555	8,145,555
			<u> </u>	<u> </u>
Net book value				
At 30 June 2025			2,884,000	2,884,000
			<u> </u>	<u> </u>
At 30 June 2024			2,884,000	2,884,000
			<u> </u>	<u> </u>
4. Holdings in related undertakings				
Cloughjordan Pharmacy Ireland Limited	Retail Pharmacy			95%
5. Creditors			2025	2024
Amounts falling due within one year			€	€
Accruals			2,152	2,152
			<u> </u>	<u> </u>
6. Income Statement				
	Share premium account	Revaluation reserve	Profit and loss account	Total
	€	€	€	€
At 1 July 2024	669,708	1,465,000	749,210	2,883,918
	<u> </u>	<u> </u>	<u> </u>	<u> </u>
At 30 June 2025	669,708	1,465,000	749,210	2,883,918
	<u> </u>	<u> </u>	<u> </u>	<u> </u>
7. Capital commitments				
The company had no material capital commitments at the financial year-ended 30 June 2025.				
8. Related party transactions				
The material related party transactions which took place between the company and its directors during the period were as follows:				
- Owed by Cloughjordan Pharmacy Limited (Subsidiary Company with common Directors) at 30/06/2022 - € NIL				
Transactions with group companies include ...				
The material related party transactions which took place between the company and its directors during the period were as follows:				
- Owed by Cloughjordan Pharmacy Limited (Subsidiary Company with common Directors) at 30/06/2022 - € NIL				

Peter Fox Pharmacy Holdings Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

9. Post-Balance Sheet Events

There have been no significant events affecting the company since the year end.

10. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 31 October 2025.